Article
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Leukemia research - 1 Jul 2014
Bally Cecile, Adès Lionel, Renneville Aline, Sebert Marie, Eclache Virginie, Preudhomme Claude, Mozziconacci Marie-Joelle, de The Hugues, Lehmann-Che Jacqueline, Fenaux Pierre
Abstract excerpt
TP53 mutations are found in 5-10% of MDS and AML, where they are generally associated with complex karyotype and an overall poor prognosis. However, the impact of TP53 mutations in MDS treated with azacitidine (AZA) remains unclear. We analyzed TP53 mutations in 62 patients with high risk MDS or AML treated with AZA. A TP53 mutation was found in 23 patients (37.1%), associated with complex karyotype in 18 (78.3%)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.